SILLAJEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,550 KRW | -0.33% |
|
+2.36% | -24.54% |
| Sales 2022 | 5.01B 3.64M | Sales 2023 | 3.94B 2.86M | Capitalization | 620B 451M |
|---|---|---|---|---|---|
| Net income 2022 | -24.59B -17.88M | Net income 2023 | -20.37B -14.81M | EV / Sales 2022 | 131 x |
| Net cash position 2022 | 59.87B 43.53M | Net cash position 2023 | 39.6B 28.79M | EV / Sales 2023 | 147 x |
| P/E ratio 2022 |
-29.1
x | P/E ratio 2023 |
-30.5
x | Employees | 42 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.11% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.33% | ||
| 1 week | +2.36% | ||
| Current month | -10.61% | ||
| 1 month | -14.31% | ||
| 3 months | -11.31% | ||
| 6 months | +0.33% | ||
| Current year | -24.54% |
1 week
4 465.00
5 050.00
1 month
4 325.005 320.00
Current year
4 325.006 620.00
1 year
3 950.007 260.00
3 years
3 950.0016 550.00
5 years
3 950.0065 900.00
10 years
3 950.00152 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Kyung-Mi Yang
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Ji-Won Choi
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Yong-Jae Jang
BRD | Director/Board Member | 57 | - |
Myung-Seok Song
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4,550 | -0.33% | 515,685 |
| 24-04-25 | 4,565 | -0.98% | 2,950,692 |
| 24-04-24 | 4,610 | +1.88% | 1,701,022 |
| 24-04-23 | 4,525 | -0.22% | 420,121 |
| 24-04-22 | 4,535 | +2.02% | 499,726 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -24.54% | 342M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- A215600 Stock
